摘要
目的比较FND(氟达拉滨+米托蒽醌+地塞米松)与CHOP(环磷酰胺+阿霉素+长春新碱+强的松)方案治疗惰性淋巴瘤的疗效与安全性。方法临床观察的内容包括缓解率[总有效率和完全缓解(CR)率],无失败生存(FFS)及毒性反应。56例患者随机分组,FND和CHOP组各28例。FND方案:氟达拉滨30mg·m-2·d-1d1～3静脉注射,米托蒽醌10mgd1静脉注射,地塞米松20mgd1～5静脉注射。平均接受6.7个化疗方案。CHOP方案:环磷酰胺600mg·m-2·d-1d1静脉注射,阿霉素25mg·m-2·d-1d1静脉注射,长春新碱1.4mg·m-2·d-1d1静脉注射和强的松50mg·m-2·d-1d1～5口服。平均接受7.1个化疗方案。以上两方案均为28d一次。结果 FND方案的完全缓解率和总有效率显著优于CHOP方案(总有效率82.1%vs57.1%,CR53.6%vs32.1%;P<0.01)。2年无疾病进展生存(PFS)率FND组为86.7%而CHOP组为66.7%。两种治疗方案的耐受性均较好。结论 FND方案的CR率、总有效率均显著优于CHOP方案,并可有效改善预后。
Objective To compare the efficacy and safety of fludarabine-mitoxantrone-dexamethason（FND） with CHOP regimen （cyclophosphamide doxorubicin,adriamycin,vincristine,prednisone） in the treatment of indolent non-Hodgkin′s lymphoma.Methods Totally 56 patients with identified indolent lymphoma who were admitted in our department from December 2002 to Feburary 2007 were enrolled in this study and then randomized into 2 groups（n=28）,FND regimen group and CHOP regimen group.FND regimen：fludarabine 30 mg·m-2·d-1,iv,day 1 to 3; mitoxantrone,10 mg,iv,day 1;dexamethason 20 mg,iv,day 1 to 5.The patients of FND received 6.7 times of plans on average.CHOP regimen：cyclophosphamide doxorubicin 600 mg·m-2·d-1,iv,day 1;adriamycin,25 mg·m-2·d-1,iv,day 1;vincristine1.4 mg·m-2·d-1,iv,day 1;prednisone 50 mg·m-2·d-1,orally taken,day 1 to 5.These patients received an average of 7.1 times.The chemotheraputic interval was 28 d.End points were remission rates,including overall response （OR） and complete response （CR）,failure-free survival （FFS） and toxicity.Results FND therapy resulted in superior remission rates with OR accounting for 82.1% and CR for 53.6% （57.1% and 32.1% respectively in CHOP group,P0.01）.The rate of progression-free survival （PFS） in 2 years for FND patients was 86.7%,compared with 66.7% for CHOP patients.Both treatments were well tolerated.Conclusion FND regimen is more effective than CHOP in achieving OR and CR for indolent lymphoma,and favorably improves the outcome.
出处
《重庆医学》
CAS
CSCD
北大核心
2010年第12期1520-1521,共2页
Chongqing medicine
